How to Get Testosterone Enanthate in New Hampshire

Who Qualifies for Testosterone Enanthate in New Hampshire

The diagnosis comes first. The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy only for men with symptomatic androgen deficiency confirmed by two separate morning serum total testosterone measurements below 300 ng/dL [1]. Symptoms must be present. Low numbers alone do not justify a prescription.

Common qualifying symptoms include persistent fatigue, decreased libido, erectile dysfunction, loss of lean mass, depressed mood, and reduced bone mineral density. New Hampshire prescribers follow the same diagnostic threshold used nationally. The American Urological Association (AUA) guideline also endorses a total testosterone cutoff of 300 ng/dL, measured by a reliable assay between 8:00 and 10:00 AM [2].

Men with a history of polycythemia (hematocrit above 54%), untreated severe obstructive sleep apnea, uncontrolled heart failure, or a desire for near-term fertility should discuss alternatives with their provider. The FDA-approved prescribing information for testosterone enanthate lists these as relative or absolute contraindications [3]. Prostate cancer and male breast cancer remain absolute contraindications per the label.

Required Lab Work Before Starting TRT in New Hampshire

Labs are not optional. Every prescriber in New Hampshire should order a baseline panel before writing the first prescription.

The minimum panel includes two fasting morning total testosterone draws, a complete blood count (CBC) with hematocrit, a prostate-specific antigen (PSA) test for men over 40, a comprehensive metabolic panel, and a fasting lipid panel. The Endocrine Society guideline also recommends measuring LH and FSH to differentiate primary from secondary hypogonadism [1]. A prolactin level may be added if secondary hypogonadism is suspected.

Quest Diagnostics and Labcorp both operate draw sites across New Hampshire, including locations in Manchester, Nashua, Concord, and Portsmouth. Many telehealth TRT providers will send a requisition to one of these labs or to an independent CLIA-certified facility. Results typically return within 48 to 72 hours. Some clinics offer at-home phlebotomy kits that ship to a central lab, though turnaround may extend to five business days.

Monitoring labs at 3 months, 6 months, and then every 6 to 12 months on therapy should include total testosterone (drawn midway between injections or at trough), hematocrit, PSA, and a metabolic panel [1].

Telehealth Options for Testosterone Enanthate in New Hampshire

New Hampshire permits telehealth prescribing of controlled substances, including Schedule III compounds like testosterone enanthate. This means a licensed provider can evaluate you, review your labs, and transmit an electronic prescription to a pharmacy without an in-person visit [4].

The state does not require an initial face-to-face encounter for telehealth prescribing, though some insurers may have their own requirements. During your video consultation, the provider will review your lab results, assess symptoms using a validated instrument such as the Androgen Deficiency in Aging Males (ADAM) questionnaire, and discuss risks and benefits. If criteria are met, the prescription is sent electronically to the pharmacy of your choice.

Dr. Abraham Morgentaler, associate clinical professor of urology at Harvard Medical School, has stated: "The fear of testosterone therapy has been based on a myth. The evidence overwhelmingly supports its safety and benefit for men who are truly deficient" [5]. This perspective aligns with the shift toward broader telehealth access for TRT across states like New Hampshire.

Telehealth visits for TRT typically last 20 to 30 minutes. Follow-up appointments are often shorter and focus on lab review and dose adjustments. Most telehealth TRT clinics in New Hampshire can schedule an initial visit within 3 to 7 days of signing up.

How New Hampshire Pharmacies Dispense Testosterone Enanthate

Both retail chain pharmacies and 503A compounding pharmacies in New Hampshire can fill testosterone enanthate prescriptions. The drug is available as a commercially manufactured product (brand Delatestryl and generics) at CVS, Walgreens, Rite Aid, and independent pharmacies statewide.

503A compounding pharmacies operate under a patient-specific prescription model. They can compound testosterone enanthate in customized concentrations (commonly 200 mg/mL in sesame oil or grapeseed oil) when a prescriber determines that a commercially available product does not meet a patient's medical needs [6]. New Hampshire's Board of Pharmacy licenses these facilities, and they may ship within the state. A 503A pharmacy cannot distribute compounded testosterone without a valid individual prescription.

The FDA's guidance on 503A compounding requires that the compound be made in response to a specific patient prescription and that the pharmacy not compound regularly or in inordinate amounts [6]. Patients should confirm that their chosen compounding pharmacy holds a current New Hampshire Board of Pharmacy license.

Pricing without insurance typically ranges from $30 to $90 per 5 mL vial (200 mg/mL) at retail pharmacies. Compounded testosterone enanthate often costs $50 to $120 for a 10 mL vial, depending on concentration and carrier oil.

Insurance Coverage and Prior Authorization in New Hampshire

Coverage depends heavily on the plan. Here is the breakdown.

Commercial insurance: Most major plans in New Hampshire, including those offered by Anthem, Cigna, Harvard Pilgrim, and Ambetter, cover testosterone enanthate for diagnosed male hypogonadism. Prior authorization is commonly required. The documentation package typically must include two morning testosterone levels below 300 ng/dL, chart notes describing symptoms, and the specific ICD-10 code (E29.1 for testicular hypofunction) [7].

New Hampshire Medicaid (NH Healthy Families): Testosterone enanthate is not covered for male hypogonadism under New Hampshire's Medicaid program. Patients on Medicaid may need to explore self-pay options or patient assistance programs.

Medicare Part D: Testosterone enanthate is generally covered under Medicare Part D formularies with prior authorization. Copays vary by tier and plan, typically falling between $10 and $45 per fill.

The AUA guideline notes that "testosterone therapy should be offered to men with symptomatic testosterone deficiency to induce and maintain secondary sex characteristics and to improve sexual function, sense of well-being, and bone mineral density" [2]. Prior authorization documentation that aligns with this guideline language tends to succeed at higher rates.

If a prior authorization is denied, New Hampshire insurance regulations allow you to file a formal appeal. Your prescriber can submit a peer-to-peer review with the plan's medical director. Turnaround on initial prior authorizations is typically 48 to 72 hours for commercial plans and up to 14 calendar days for Medicare Part D.

Who Can Prescribe Testosterone Enanthate in New Hampshire

New Hampshire allows physicians (MD and DO), nurse practitioners (APRN), and physician assistants (PA-C) to prescribe Schedule III controlled substances, including testosterone enanthate.

Nurse practitioners in New Hampshire have full practice authority under RSA 326-B, meaning they can prescribe independently without a collaborative agreement with a physician [8]. This is relevant for TRT because it expands the number of providers who can initiate and manage therapy, particularly in rural areas of the state where endocrinologists or urologists may be scarce.

Physician assistants prescribe under a collaborative agreement with a supervising physician, though the physician does not need to be physically present. Both APRNs and PAs must hold active DEA registrations and New Hampshire Controlled Drug Act registrations to prescribe testosterone.

For patients in northern New Hampshire or the Lakes Region, telehealth prescribers licensed in the state offer a practical alternative to driving hours for a specialist visit. Any prescriber writing the script must be licensed by the New Hampshire Board of Medicine or Board of Nursing.

What to Expect: Timeline from Consultation to First Injection

The process has defined steps and a predictable timeline.

Days 1 to 3: Complete lab work. If using a telehealth provider, you will receive a lab requisition after signing up. Walk-in labs at Quest or Labcorp locations in Manchester, Nashua, or Concord can draw blood the same day.

Days 3 to 5: Lab results return. Your provider reviews the results and schedules a video or in-person consultation.

Days 5 to 10: Consultation and diagnosis. If testosterone levels confirm hypogonadism and symptoms are present, the provider writes the prescription. Electronic prescriptions for Schedule III drugs are transmitted directly to the pharmacy.

Days 10 to 14: Pharmacy fills the prescription. Retail pharmacies typically fill within 1 to 3 days. Compounding pharmacies may require 5 to 7 business days, especially for custom formulations.

Days 14 to 21: First injection. Most patients self-administer at home after training, or receive their first injection at a provider's office. The standard starting dose is 100 mg IM weekly or 200 mg IM every two weeks, per the FDA label [3].

In the landmark Testosterone Trials (TTrials), 790 men aged 65 and older with low testosterone received testosterone gel or placebo for 12 months. The testosterone group showed improvements in sexual function, physical activity, and mood, with sexual function showing the largest benefit (P<0.001 for the difference vs. placebo) [9]. While TTrials used a gel formulation, the physiological endpoints apply to enanthate injections that achieve similar serum levels.

Transferring an Existing Prescription to New Hampshire

If you already have a testosterone enanthate prescription from another state, transferring it to a New Hampshire pharmacy is straightforward for remaining refills. The receiving pharmacy contacts the transferring pharmacy directly. Because testosterone enanthate is Schedule III, federal law limits transfers to one transfer per prescription unless both pharmacies share a real-time online database [10].

For patients moving to New Hampshire permanently, establishing care with a local or telehealth provider licensed in the state is the more sustainable option. Your new provider can request medical records from your previous clinic, review your most recent labs, and continue your regimen without a gap in therapy. Most telehealth clinics can accomplish this within one week.

Patients relocating should bring or have forwarded: recent lab results (within the past 6 months), a copy of the current prescription, and any prior authorization documentation from their insurance plan.

Safety Monitoring and Long-Term Management

Testosterone therapy is not a set-and-forget treatment. The Endocrine Society recommends measuring hematocrit at baseline, 3 months, 6 months, and annually thereafter [1]. If hematocrit exceeds 54%, the dose should be reduced or therapy paused until the value normalizes.

A 2019 pharmacovigilance analysis published in JAMA Internal Medicine found that among 15,401 men initiating testosterone therapy, the rate of major adverse cardiovascular events did not differ significantly from matched controls over a median 3.4-year follow-up (HR 0.97 to 95% CI 0.83 to 1.14) [11]. The more definitive TRAVERSE trial (N=5,204) published in the New England Journal of Medicine in 2023 confirmed that testosterone replacement in men aged 45 to 80 with hypogonadism and cardiovascular risk factors was noninferior to placebo for major cardiovascular events (HR 0.99 to 95% CI 0.81 to 1.21) [12].

Dr. Shalender Bhasin, director of the Research Program in Men's Health at Brigham and Women's Hospital, stated regarding the TRAVERSE findings: "This trial provides reassurance that testosterone therapy, when appropriately prescribed for men with hypogonadism, does not increase cardiovascular risk" [12].

PSA should be monitored at baseline and at 3 to 6 months. A confirmed PSA increase greater than 1.4 ng/mL within 12 months or a velocity exceeding 0.4 ng/mL per year should prompt urological referral [1]. Bone density testing (DEXA) is appropriate for men with osteoporosis or osteopenia at baseline, with repeat scanning at 1 to 2 years on therapy.